Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged

BIOXYTRAN, INC

JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.
Heme Foundation pledges up to $10M over project; $2M already invested in prototypes and compounds.
Total development cost estimated $20M-$25M over 3.5 to 5 years; Bioxytran retains IP.
Two successful small animal trials (mice, rabbits) completed; large 14-day toxicology study planned.
UOC compatible with all blood types, shelf-stable 5+ years, 18-hour half-life, no known side effects.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.